Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action

American Journal of Transplantation

Volumn 6, Issue 5 I, 2006, Pages 859-866

  Pescovitz, M D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Anti CD20; Mechanism; Pharmacokinetics; Rituximab; Transplant

Indexed keywords

CD20 ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; CD20 ANTIGEN; IMMUNOLOGIC FACTOR;

CELL MIGRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG USE; GRAFT RECIPIENT; HALF LIFE TIME; HUMAN; IN VITRO STUDY; OFF LABEL DRUG USE; PRIORITY JOURNAL; SHORT SURVEY; B LYMPHOCYTE; CHEMISTRY; HISTOCOMPATIBILITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MYASTHENIA GRAVIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MYASTHENIA GRAVIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TRANSPLANTATION IMMUNOLOGY;

EID: 33745263037     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01288.x     Document Type: Short Survey

References (91)

1. Inoue K, Niesen N, Milgrom F, Albini B. Humoral transplantation antibodies play a role in protracted rejection of murine renal allografts. Int Arch Allergy Appl Immunol 1991; 96: 253-258.
2. Milgrom F. Humoral transplantation antibodies. Transplant Proc 1999; 31: 30-33.
3. Cai J, Terasaki PI. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334-342.
4. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67: 134.
5. Treon SP, Shima Y, Raje N et al. Interferon-g induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells. Blood 2000; 94 (Suppl 1): 119a.
6. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J 1988; 7: 711-717.
7. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
8. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
9. Tobinai K, Kobahashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998; 9: 527-534.
10. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548.
11. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 393-403.
12. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
13. Ghielmini M, Rufibach K, Salles G et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675-1682.
14. Emery P, Filipowicz-Sosnowska A, Szczepanski L et al. Primary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER TRIAL). Ann Rheum Dis 2005; 64 (Suppl III): 434.
15. Book BK, Agarwal A, Milgrom AB et al. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 2005; 37: 640-642.
16. Bearden CM, Book BK, Sidner RA, Pescovitz MD. Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing. J Immunol Methods 2005; 300: 192-199.
17. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88 (Suppl 1): 637.
18. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459.
19. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
20. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
21. Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu Rev Immunol 2005; 23: 161-196.
22. Goodyear CS, Silverman GJ. B cell superantigens: A microbe's answer to innate-like B cells and natural antibodies. Springer Semin Immunopathol 2005; 26: 463-484.
23. Qian J-H, Hashimoto T, Fujiwara H, Hamaoka T. Studies on the induction of tolerance to alloantigens I. The abrogation of potentials for delayed-type-hypersensitivity responses to alloantigens by portal venous inoculation with allogeneic cells. J Immunology 1985; 134: 3656-3661.
24. Genberg H, Hansson A, Wernerson A, Tyden G. Effective B-cell depletion in peripheral blood and tissue by single-dose rituximab in kidney transplant recipients: A pilot study. Am J Transplant 2005; 5 (Suppl 11): 397.
25. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003; 12: 19-28.
26. McLaughlin P, Grillo-Lopez A, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
27. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55-62.
28. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse, and the complication. Transplantation 2002; 73: 100-104.
29. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology 2001; 40: 205-211.
30. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888.
31. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4: 1357-1360.
32. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant 2005; 24: 628-630.
33. Pescovitz MD, Breen N, Book BK et al. OKT3 treatment of acute renal allograft rejection in children. Clin Transplantation 1992; 6: 184-190.
34. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
35. Tsutsumi Y, Kanamori H, Mori A et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608.
36. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061.
37. Agarwal A, Sidner RA, Fridell JA et al. Immunomodulatory impact of rituximab and thymoglobuin therapy in liver transplantation. Am J Transplant 2005; 5(suppl 11): 1239.
38. Saville MW, Benyunes MC, Multani PS. No clinical evidence for CD4+ cell depletion caused by rituximab. Blood 2003; 102: 408-409.
39. van der Kolk LE, Baars JW, Prins MH, van Oers MHJ. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257-2259.
40. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD, Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clinical Immunology 2001; 98: 175-179.
41. Bearden CM, Agarwal A, Book BK et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5: 50-57.
42. Norin S, Kimby E, Ericzon BG et al. Posttransplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol 2004; 21: 273-284.
43. Caillard S, Pessione F, Moulin B, the French PTLD Working Group. Post-transplant lymphoproliferative disorders (PTLD) in kidney transplantation: Report of 220 cases of a French registry. Am J Transplant 2005; 5 (Suppl 11): 360.
44. Tobinai K. Rituximab and other emerging monoclonal antibody therapies for lymphoma. Expert Opin Emerg Drugs 2002; 7: 289-302.
45. Luke PP, Scantlebury VP, Jordan ML et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419-422.
46. 2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nature Med 2003; 9: 431-438.
47. Pescovitz MD, Book BK, Rahman A, Viera CA, Susskind BM. Measurement of HLA antibody specificity by single antigen beads and MESF quatitation demonstrates efficacy of rituximab desensitization. Am J Transplant 2005; 5 (Suppl 11): 324.
48. Slifka MK, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10: 252-258.
49. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372.
50. Bernasconi N, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-2202.
51. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003; 63: 2836-2843.
52. Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: Antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001; 13: 1583-1593.
53. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
54. Hippen BE, DeMattos A, Cook WJ, Kew CE, II, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248-2252.
55. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005; 19: 137-140.
56. Vugmeyster Y, Beyer J, Howell K et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005; 28: 212-219.
57. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 282-289.
58. Peter HH, Warnatz K. Molecules involved in T-B co-stimulation and B cell homeostasis: Possible targets for an immunological intervention in autoimmunity. Expert Opin Biol Ther 2005; 5 (Suppl 1): S61-71.
59. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-116.
60. Culic S, Culic VV, Armanda V, Kuljis D, Pesutic-Pisac V, Jankovic S. Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20-positive large B-Cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol 2003; 20: 339-344.
61. Bueno J, Ramil C, Somoza I et al. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatr Transplant 2003; 7: 153-156.
62. Herman J, Vandenberghe P, van den Heuvel I, Van Cleemput J, Winnepenninckx V, Van Damme-Lombaerts R. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. J Heart Lung Transplant 2002; 21: 1304-1309.
63. Berney T, Delis S, Kato T et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002; 74: 1000-1006.
64. Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O. Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002; 34: 389-393.
65. Webber SA, Fine RN, McGhee W, Harmon W, Sarwal M, Faro A. Anti-CD20 monoclonal antibody (rituximab) for pediatric posttransplant lymphoproliferative disorders: A preliminary multicenter experience. Am J Transplant 2001; 1 (Suppl 1): 469.
66. Chen LJ, Nepomuceno RR, Beatty PR, Krams SM, Esquivel CO, Martinez OM. CD20 ligation using rituximab (anti-CD20 monoclonal antibody) inhibits growth of EBV infected B cells from a patient with PTLD. Transplantation 2000; 69 (Suppl):S331.
67. Roithmann S, Bonamigo-Filho JL, Neumann J, Fogliatto L, Gaiger AM, Garcia VD. Anti-CD20 monoclonal antibody (rituximab) for post-transplant lymphoproliferative disease treatment (PTLD). Blood 2000; 96: 246b.
68. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20: 770-772.
69. Dotti G, Rambaldi A, Frocchi R et al. Anti-CD20 antibody rituximab administration in patients with late-occurring lymphomas after solid organ transplant. Haematologica 2001; 86: 618-623.
70. Horwitz SM, Tsai D, Twist C, Sarwal M, Breslin S, Dahl G. Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: A prospective trial in adults and children. Proc Am Soc Clin Oncol 2001; 20: 284a.
71. Ganjoo J, Green M, Sindhi R, Mazariegos G, Reyes J. Lymphocyte subsets may discern treatment effects in children with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2001; 1 (Suppl 1): 287.
72. Mazariegos GV, McGhee W, Sindhi R, Reyes J. Thymoglobulin (T) in the management of steroid resistant acute cellular rejection (SRACR) in children. Am J Transplant 2001; 1 (Suppl 1): 311.
73. Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr Transplant 2004; 8: 9-21.
74. Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906.
75. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase II study. Blood 2005.
76. Kawagishi N, Satoh K, Enomoto Y et al. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange. Transplant Proc 2005; 37: 1205-1206.
77. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322.
78. Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18: 254-260.
79. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.
80. Usuda M, Fujimori K, Koyamada N et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 12-16.
81. Segev DL, Simpkins CE, Warren DS et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2570-2575.
82. Koyama I, Fuchinoue S, Kai K et al. Successful ABO-incompatible kidney transplantation for non-responders with the use of anti-CD20 monoclonal antibody and plasmapheresis. Am J Transplant 2005; 5 (Suppl 11): 183.
83. Diaz A, Thielke J, Pham T et al. Successful kidney transplant in ABO incompatible patients after plasmapheresis and thymoglobulin under a steroid avoidance protocol. Am J Transplant 2005; 5 (Suppl 11): 324-325.
84. Gloor J, Moore S, Pineda AA et al. Living donor kidney transplantation in positive crossmatch patients. Am J Transplant 2003; 3 (Suppl 5): 200.
85. Samaniego M, Zachary A, Lucas D et al. Early allograft outcomes in patients with antibody mediated rejection treated with rituximab. Am J Transplant 2002; 2 (Suppl 3): 259.
86. Garrett HE, Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002; 74: 1240-1242.
87. Aranda J, Scornik JC, Normann SJ et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: A case report. Transplantation 2002; 73: 907-910.
88. Goldstein MJ, Lee S, Guarrera JV, Cohen DJ, Hardy MA. Rituximab rescue for refractory antibody mediated rejection after kidney transplantation. Am J Transplant 2005; 5 (Suppl 11): 397-398.
89. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
90. Stegall MD, Moore SB, Gloor JM, von Liebig WJ. Achieving desensitization and preventing humoral rejection in positive crossmatch living donor kidney transplantation. Am J Transplant 2005; 5 (Suppl 11): 292-293.
91. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660-1663.